|
KR20200050374A
|
|
Srm/mrm assays for notch pathway proteins
|
|
CN110678203A
|
|
Prediction of therapeutic effect of gastric cancer
|
|
KR20200016242A
|
|
Prediction of Cancer Treatment Results by T-DM1
|
|
KR20190127732A
|
|
Immune Profiling of Tumor Tissue
|
|
US2020271654A1
|
|
Quantifying MGMT Protein For Optimal Cancer Therapy
|
|
US2018180628A1
|
|
Methods of treating cancer by identification of patients sensitive to fgfr inhibitor therapy
|
|
US2019353658A1
|
|
Improved Methods Of Treating Lung Cancer Using Multiplex Proteomic Analysis
|
|
WO2018102797A1
|
|
Srm/mrm assays for cd56 and chga proteins
|
|
WO2018102827A1
|
|
Improved methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy
|
|
WO2018089754A1
|
|
Srm/mrm assays for cancer
|
|
US2018112277A1
|
|
Signal directed dissection to inform cancer therapy strategy
|
|
CN109863405A
|
|
SRM/MRM for tubulin β -3 chain (TUBB3) albumen is measured
|
|
EP3464646A2
|
|
Detection of exon 14 deletion in the met protein
|
|
US2018172690A1
|
|
Method for improved hepatocellular cancer diagnosis
|
|
US2019293652A1
|
|
Quantifying KRAS for Optimal Cancer Therapy
|
|
WO2017120376A1
|
|
Quantifying protein for optimal cancer therapy
|
|
US2017168055A1
|
|
SRM/MRM Assays
|
|
WO2017100663A1
|
|
Improved methods for treating her2-positive breast cancer
|
|
US2017097354A1
|
|
Quantifying met protein for cancer treatment
|
|
EP3328387A1
|
|
Quantifying fr- and gart proteins for optimal cancer therapy
|
